Japan Patient Support Programs (PSP) Market Analysis Sample Report

Japan Patient
Support Programs
(PSP) Market Analysis
A sample report on
www.insights10.com
Includes Market Size, Market Segmented by Types
and Key Competitors (Data forecasts from 2022 – 2030F)

This report presents a strategic analysis of the Japan Patient Support
Programs (PSP) Market and a forecast for its development in the
medium and long term. It provides a comprehensive overview of the
market value, dynamics, segmentation, types of clinical diagnostics, point-
of-care testing, main players, growth and demand drivers, challenges &
future outlook, etc. This is one of the most comprehensive reports about
the Japan Patient Support Programs (PSP) Market, and offers
unmatched value, accuracy, and expert insights

3
A Sample Report on Japan Patient Support Programs (PSP) Market Analysis I Confidential
Report Scope
Report Attribute Details
Number of Pages 70-80
Base Year for Estimation 2022
Forecast Period 2023-2030
Report Coverage
Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends,
Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape,
Reimbursement Scenario
Quantitative Units Revenue in USD Million/Billion (Mn/Bn)
Research Approach Secondary Research (60%), Primary Research (40%)
Click on the icon to know the detailed methodology

4
Table of Content
CONTENT PG. NO.
1. Patient Support Programs (PSP) Overview 12-25
1.1. Overview
1.2. Japan Overview
1.3. Economic Overview: Japan
1.4. Patient Support Programs (PSP) Market in Japan
1.5. Healthcare Services Market in Japan
1.6. Healthcare Scenario in Japan
1.7. Health Insurance Coverage: Japan
1.8. Budget of the Government for Public Insurance
1.9. Mergers and Acquisitions
2. Market Size and Forecasting 26-32
2.1 Market size and forecasts (Excel and Methodology)

5
Table of Content
CONTENT PG. NO.
2.2. Market Segmentation
2.2.1. Functionality outlooks
2.2.2. Therapeutic area outlook
2.2.3. Application outlook
2.2.4. End-user
3. Market Dynamics 33-37
3.1. Market Growth Drivers
3.1.1. Japan Patient Support Programs (PSP) Market Driver 1
3.2. Market Restraints
3.2.1. Japan Patient Support Programs (PSP) Market Restraint 1

6
Table of Content
CONTENT PG. NO.
4. Competitive Landscape 38-48
4.1. Major Market Share
4.2. Key Company Profile
4.2.1. Takeda Pharmaceutical Company
4.2.1.1. Overview
4.2.1.2. Product Applications & Services
4.2.1.3. Recent Developments
4.2.1.4. Partnerships Ecosystem
4.2.1.5. Financials (Based on Availability)
4.2.2. Astellas Pharma
4.2.2.1. Overview

7
Table of Content
CONTENT PG. NO.
4.2.3. Daiichi Sankyo
4.2.3.1. Overview
4.2.4. Eisai
4.2.4.1. Overview

8
Table of Content
CONTENT PG. NO.
4.2.5. Otsuka Pharmaceutical
4.2.5.1. Overview
4.2.6. Eli Lilly Japan K.K.
4.2.6.1. Overview

9
Table of Content
CONTENT PG. NO.
4.2.7. Sanofi
4.2.7.1. Overview
4.2.8. Pfizer Japan
4.2.8.1. Overview

10
Table of Content
CONTENT PG. NO.
4.2.9. AbbVie
4.2.9.1. Overview
4.2.10. Cancer Support Community Japan
4.2.10.1. Overview

11
Table of Content
CONTENT PG. NO.
5. Reimbursement Scenario 49-56
5.1. Reimbursement Regulation
5.2. Reimbursement Process for Diagnosis
5.3. Reimbursement Process for Treatment
5.4 Reimbursement Process – Medicare
5.5 Reimbursement Process - Medicaid
6. Methodology & Scope 57-62

Japan Patient Support Programs (PSP) Market Analysis
1. Patient Support Programs (PSP) Overview

13
1.1 Statistics at a Glance: Patient Support Programs (PSP) in the World
Patient Support Programs (PSP) at
Global level ▪ Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪ In this section you will get an
understanding of the topic, which includes
the prevalence of the disease, the
application of medical devices, new
technology, and other details related to the
topic
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
90%
Was PSPs impact
adherence after one
year
32%
Is the percentage increase in
number of PSP in the US
Key reasons
For the impact of PSP are unaffordability and non-adherence to the
treatments
$70.3 Bn
Is the forecasted
valuation of Global
PSP market for
year 2030
17.4%
Is the CAGR of the Global
PSP market for the period of
2023-2030

14
1.1 Statistics at a Glance: The Status of Patient Support Programs (PSP) in the
World (continued)
North America
~ Market Size of
$xx Bn
Europe
~Revenue to reach
$xx Bn by 2027
Asia
-Fastest CAGR of
xx%
Africa
~Market Size of $xx
Bn
Egypt Market
~$xx Mn Market
Illustrative

15
1.2 Japan Overview
125.8 Mn
Is the population of
Japan, in 2022
48.4 years
Is the median age
in Japan, in 2022
5.15 Tn
Is the Gross
Domestic Product
(GDP) in Japan in
2021
$5.5k
per capita was the
amount of national
health expenditures in
2021
▪ Please be aware that this sample report is
report
understanding of the demographics of the
country/region, which includes the
population, GDP, healthcare expenditure
and other details related to the topic
interest

16
1.3 Economic Overview: Japan
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
Population of Japan, (2020-2030)
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
GDP of Japan, (2020-2030)
Population Split (2023)
55-64
0-14
15-24
25-54
65+
Male
49%
Female
51%
By Age Group
By Gender
▪ In this section you will get an understanding of the demographics
of the country/region, which includes the population, GDP,
healthcare expenditure and other details related to the topic
▪ In order to obtain access to all of the information that you are
seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will
include data, analysis, trends, and other relevant information
related to the topic or subject matter of interest
Illustrative

17
1.4 Statistics at a Glance: Patient Support Programs (PSP) in Japan
Prevalence of Patient Support Programs
(PSP)
▪ Please be aware that this sample report
is intended to provide you with a brief
analysis that will be presented in the
final report
understanding of the topic, which
includes the prevalence of the disease,
the application of medical devices, new
technology, and other details related to
the topic in Japan
information that you are seeking, you
will need to purchase the final report
detailed, and it will include data,
analysis, trends, and other relevant
information related to the topic or
subject matter of interest
▪ Individualized Medication Counselling
▪ Call Center Support
▪ Patient Advocacy
Are the services provided by Patient Support Programs in Japan
▪ Pharmaceutical Companies
▪ Healthcare Providers and Institutions
▪ Patient Advocacy Groups
▪ Government Agencies
▪ Non-profit Organizations
Are the main providers of Patient Support Programs in Japan

18
1.5 Healthcare Services in Japan
xx xx xx xx xx xx xx xx xx
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Japan PSP Market Forecast, 2022-2030 (in $Bn)
▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be
presented in the final report
▪ In this section you will get an understanding of the overall Healthcare Services market in Japan, which includes the market size, current
trends and other details related to the topic
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or
Illustrative

19
1.6 Healthcare Scenario in Japan
Cancer Drug Development Process: The process of developing a cancer drug is complex and involves many stages, from preclinical research
to clinical trials to regulatory approval. Here is a simplified diagram of the cancer drug development process:
o Preclinical Research: Researchers identify potential drug candidates and test them in the lab
o Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans
o Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating cancer
o Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and
effectiveness
o Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for use in the US market
Fast Track
▪ Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat
serious conditions and fill an unmet medical need
Breakthrough
Therapy
▪ A process designed to expedite the development and review of drugs which may demonstrate substantial
improvement over available therapy
Accelerated
Approval
▪ These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved
based on a surrogate endpoint
Priority Review ▪ A Priority Review designation means FDA’s goal is to take action on an application within 6 months
FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and
effectiveness. Here are four of these approaches:
Illustrative

20
1.6 Healthcare Scenario: Patient Journey
Presentation Diagnosis Treatment Follow up
A suspected diagnosis is
usually made, based on
physical examination and
detailed patient and family
history
Prenatal screening/
Neonatal screening
Initial Diagnosis
Complete blood count
(evaluate number &
quality of RBCs, Hb &
WBCs)
Imaging (confirm bone
related changes or
respiratory problems)
Bacterial cultures of
blood, sputum, urine,
stool (detect any
infection)
Genetic testing (detect
the type of SCD)
Confirmatory Diagnosis
Prevention and management of
crisis:
• For VOC and Splenic
Sequestration: HU, Endari,
Adakveo, Oxbryta
• For infections: Antibiotics,
Vaccines
Prevention and management of
complications:
• Stroke: Chronic transfusions, HU
• Long term follow-up is required for
patients with SCD
• Annual assessment: CBC and
reticulocyte count, iron status, liver
and renal function tests, urinalysis,
LDH, vitamin D level and
neurocognitive assessment
• ESOD (End Stage Organ Damage)
evaluation starting from age 7
• Yearly Transcranial Doppler test to
determine risk of stroke
Stakeholders
PCP, paediatrician,
neonatologist,
haematologist and genetic
counsellor
PCP, pediatrician, medical geneticist,
hematologist, gynecologist and pathologist
PCP, pediatrician, medical geneticist,
cardiologist, hematologist,
endocrinologist, psychologist and
psychiatrist
PCP, pediatrician, neonatologist,
endocrinologist, cardiologist,
hematologist, orthopedist, psychologist
and psychiatrist
Depending on the organ complications,
the treatment involves different
specialists at different times
Illustrative

21
1.7 Health Insurance Coverage: Japan
1.0
18.9
18.4
35.7
2.5
3.5
10.2
54.3
66.0
91.7
8.3
VA and CHAMPVA
Medicaid
Medicare
Any public plan
TRICARE
Marketplace
Direct-purchase
Employment-based
Any private plan
With health insurance
Uninsured
▪ In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire
calendar year
▪ More people had private health insurance (66%) than public coverage (35.7%)
▪ Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%),
followed by Medicaid (18.9%), Medicare (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care
(1%)
Coverage Type 2020 2021 Change %
Total 327,521 328,074
Any health plan 299,230 300,887 0.4
Any private plan 217,896 216,366 –0.6
Employment-based 178,737 178,285 –0.2
Direct-purchase 33,869 33,555 –0.1
Marketplace coverage 10,924 11,389 0.1
TRICARE 9,165 8,299 –0.3
Any public plan 112,925 117,095 1.2
Medicare 58,541 60,226 0.5
Medicaid 58,778 61,940 0.9
VA and CHAMPVA 2,967 3,151 0.1
Uninsured 28,291 27,187 –0.4
% of People by Type of Health Insurance Coverage
(2021)
Number of People By Health Insurance Coverage
Illustrative

22
1.8 Budget of Japan Government for Public Insurance
Proposed Budget By Category
Outlays 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31
In Billions Of Dollars
Medicare $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633
Medicaid $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926
As % Of GDP
Medicare 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7%
Medicaid 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4%
▪ National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP)
▪ Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE
▪ Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE
▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE
▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE
▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE
▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020
▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020
▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020
▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health
spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7%
Illustrative

23
1.9 Mergers and Acquisitions
$6.0
$7.7
$10.5
$16.7
$6.8
$11.7
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
82
112 107 107
89
110
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020
RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend
Buyer Composition: Strategic Vs Financial (2020)
59%
41% 41%
59% 58%
42%
61%
39%
$0- $25 $25-$50 $50-$100 $100+
Strategic Buyers
Financial Buyers
Buyer Type by Deal Size
($Mn)
Illustrative

24
1.9 Mergers and Acquisitions (continued)
Company Name Type
Amount /
Duration
Year Key Pointers
Acquisition $5.9 Bn May 2023
▪ Japan's Astellas Pharma declared it agreed to buy U.S.
drugmaker Iveric Bio Inc
▪ The deal marks the fifth major overseas acquisition by Astellas,
Japan's third biggest drugmaker by sales
▪ It is the second-largest cross-border acquisition for a Japanese
drugmaker in the past five years
Acquisition $85 Mn
January
2023
▪ Moderna to Buy Japanese Firm OriCiro in Its First-Ever
Acquisition
▪ In its inaugural acquisition, Moderna will buy the Japanese
biotechnology company OriCiro Genomics and obtain its suite of
genetic engineering tools
▪ OriCiro focuses on cell-free synthesis and amplification of
plasmid DNAs
Latest Deals In Japan

25
1.9 Mergers and Acquisitions (continued)
Company Name Type
Amount /
Duration
Year Key Pointers
Merger March 2023
Merger Jan 2023
Latest Deals In Japan
Illustrative

2. Market Size and Forecasting

27
2.1 Market size and forecasts (Excel and Methodology)
XX
XX
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Japan PSP Market Forecast, 2022-2030 (in $Bn)
final report
understanding of the overall Healthcare
Insurance market in Malaysia, which
includes the market size, current trends
and other details related to the topic
Click on the icon to know the
methodology and assumption
2023 2024 2025 2026 2027 2028 2029 2030
Major Markets Patient
(Mn)
2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12
Malaysia Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73
% of US Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45%
Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937
Malaysia Market Size (Bn
$)
61 74 84 87 91 95 99 106
Illustrative

28
2.2 Snapshot of Japan PSP Market Segmentation
▪ In this section you will get an understanding of the segmentations which will cover the Japan Patient Support Programs (PSP) Market
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Functionality Outlooks
Communication
Health Tracking & Insights
Therapeutic Area Outlook
Health & Wellness
Chronic Disease
Management
Others
Application Outlook
Population Health
Management
Outpatient Health
Management
End-user
Payers
Providers
Billing & Payments
Administrative
Patient Education
In-patient Health
Management
Others
Others

29
Japan Cancer Market Share, By Functionality Outlooks (2022)
Communication
Health Tracking
& Insights
Billing &
Payments
Administrative
Patient
Education
▪ Communication market in Japan is a
significant component of the overall
cancer treatment market
▪ It has the maximum market share in
Japan cancer market with
approximately xx%
final report
2.2.1 Market Segmentation: By Functionality Outlooks

30
Japan Cancer Market Share, By Therapeutic Area Outlook (2022)
Health &
Wellness
Chronic Disease
Management
Others
2.2.2 Market Segmentation: By Therapeutic Area Outlook
▪ Health & wellness market in Japan is a
significant component of the overall
cancer market
approximately xx%
final report

31
Japan Cancer Market Share, By Application Outlook (2022)
Population
Health
Management
Outpatient
Health
Management
In-patient Health
Management
Others
2.2.2 Market Segmentation: By Application Outlook
▪ Population health management market
in Japan is a significant component of
the overall cancer market
approximately xx%
final report

32
Japan Cancer Market Share, By End User (2022)
Payers
Providers
Others
2.2.3 Market Segmentation: By End User
▪ Payers have the maximum market
share in Japan cancer market with
approximately xx%
final report

3. Market Dynamics

34
3.1 Market growth drivers
▪ Disease burden is increasing in Japan, with more than xx Mn new cancer
cases expected to be diagnosed in 2023
▪ This is driving the demand for disease treatments and creating
opportunities for growth in the PSP market
▪ Please be aware that this sample report is intended to provide you with a
brief overview of the kind of information and analysis that will be
presented in the final report
▪ In order to obtain access to all of the information that you are seeking,
you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data,
analysis, trends, and other relevant information related to the topic or
2010 2022 2030
3.1.1 Patient engagement and patient support have always been a leading concern for healthcare providers
Incidence of Cancer in Japan
Illustrative

35
3.1 Market growth drivers (continued)
Top countries that are leveraging
technology for PSP growth
United States
Japan
Germany
South Korea
China
United Kingdom
France
Canada
Australia
Israel
Switzerland
Singapore
Sweden
Netherlands
Italy
Spain
Belgium
Denmark
Austria
Norway
3.1.2 1. Leverage digital technologies to enhance patient experience and medication compliance
▪ Japan has a long history of investing in cancer research and
treatment, and as a result, has become a world leader in the
field
▪ IT has a robust healthcare infrastructure, including world-
renowned research institutions, hospitals, and clinics, that
are dedicated to cancer treatment and research
▪ One of the key factors that has allowed Japan to stay ahead
in the field of cancer research and treatment is the high level
of investment in cancer-related research
Illustrative

36
3.1 Market growth drivers (continued)
Fundings from government and other
organizations
3.1.3 4. Integrate PSP insights into your value proposition to drive brand differentiation
▪ Japan government provides significant support and funding
for cancer research and treatment, which is driving
innovation and growth in the cancer market
▪ Please be aware that this sample report is intended to
provide you with a brief overview of the kind of information
and analysis that will be presented in the final report
Source Year Fund ($)
National Cancer
Institute (NCI)
2021 $ 6.4 Bn
Centers for Disease
Control and
Prevention (CDC)
2021 $ 501 Mn
American Cancer
Society (ACS)
2020 $ 150 Mn
Susan G. Komen 2020 $ 98 Mn
Illustrative

37
3.2 Market restraints
3.2.1 In 2020, the
average cost of a new
cancer drug was over
$150,000 per year
▪ Cancer treatments can be very
expensive and can lead to
financial burden for patients and
healthcare systems
▪ Cost of cancer treatment varies
depending on the type of cancer,
stage of cancer, and treatment
options
▪ Some common cancer
treatments, such as
chemotherapy and radiation
therapy, can cost tens of
thousands of dollars
3.2.2 Average cost of
developing a new cancer
drug that is ultimately
approved by the FDA is over
$2.6 Bn
▪ Regulatory requirements for
cancer treatments can be very
stringent, which can slow down
the approval process and limit
access to new treatments
▪ Regulatory bodies, such as
Japan Food and Drug
Administration (FDA), require
extensive clinical trials and
safety data before approving
new cancer treatments
▪ This can be a lengthy and costly
process, which can delay the
availability of new treatments for
patients
3.2.3 Demand for cancer care is
expected to increase by 42% by
2025, while the supply of
oncologists is only expected to
increase by 28%
▪ There is a shortage of
oncologists in Japan, which can
limit access to cancer treatments
and create barriers to growth in
the cancer market
▪ Oncologists are physicians who
specialize in the diagnosis and
treatment of cancer
▪ With the aging population and
the increasing incidence of
cancer, there is a growing
demand for oncologists
▪ However, the supply of
oncologists is not keeping pace
with the demand
Our analysis will thoroughly investigate the key restraints that may significantly impact business
operations and growth.
Illustrative

4. Competitive Landscape

39
4.1 Major Market Share
XX
Other
▪ Japan PSP market is a highly competitive
space, with many companies developing
and marketing cancer treatments
▪ Some of the top companies in Japan
cancer market based on revenue and
market share include
▪ Takeda Pharmaceutical Company is a
Swiss multinational healthcare company
that develops and markets cancer
treatments, including targeted therapies
and immunotherapies
interest
Revenue of Major players in Japan PSP Market ($ Mn)
Illustrative

40
4.2 Key Company Profile
▪ Here is the list of top 10 companies which
will cover in the final report
▪ Each company will have slides for
o Overview
o Key details
o Offerings
o Name of products
o Recent activities/ Press Coverage
o Distribution and Vendor Partners
o Mergers, Acquisitions and
Collaboration
o Financials
▪ If there are specific companies that you
would like to be included in the report,
please let us know via email
1
Takeda Pharmaceutical
Company
3 Daiichi Sankyo
5 Otsuka Pharmaceutical
7 Sanofi
9 AbbVie
2 Astellas Pharma
4 Eisai
6 Eli Lilly Japan K.K.
8 Pfizer Japan
Cancer Support
Community Japan
10
Key Note:

41
4.2.1 Takeda Pharmaceutical Company
Founded in: 1781
HQ: Tokyo, Japan
Type: Public
Revenue: $31.8 Bn
Website: www.takeda.com
▪ It is a research-based pharmaceutical company which focuses on
the discovery, development, manufacturing, marketing,
commercialization, import and export of pharmaceutical drugs
▪ Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US,
Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland,
China, India, and Canada among others
▪ Takeda has partnership with academic institutions, small biotech,
and large pharmaceutical companies
Focus Areas of Takeda
Pharmaceutical Company
➢ Rare Diseases
➢ Gastrointestinal
➢ Oncology
➢ Neuroscience
➢ Vaccines
➢ Plasma-derived Therapies
Indications
Oncology Patient Advocacy and Engagement (PA&E)
Disease Edcuation
Takeda Oncology Here2Assist
Services offered Recent Activity / Press Coverage
Initiatives aimed at raising awareness of IBD to be close to and contribute to
IBD patients
Joint Research Results for Analysis and Visualization of the Patient Journey
of Ovarian Cancer Patients Presented at ISPOR 2023 International Society
for Pharmacoeconomic and Outcomes Research
Astellas Pharma, Eisai, Daiichi Sankyo, and Takeda Collaborate in the
Pharmaceutical Packaging Field to Reduce Environmental Impact

42
4.2.1 Takeda Pharmaceutical Company (continued)
Major Investments Licensing Agreements
Partnerships Ecosystem
▪ Oshi Health is a completely redesigned
gastrointestinal care experience
▪ Oshi Health Secures $23 Mn Series A to
Scale Transformational Virtual Specialty
Care from venture capitalists including
Takeda
▪ Flare Capital Partners, Bessemer
Venture Partners, Frist Cressey
Ventures, CVS Health Ventures and
notable angel investors back Oshi
Health’s novel, integrated care model for
gastrointestinal health
▪ Takeda to obtain exclusive worldwide
rights to develop, manufacture and
commercialize Antibody Drug Conjugates
(ADC) using a panel of selected
antibodies developed by Innate
▪ Takeda will be responsible for the future
development, manufacture and
commercialization of any potential
products developed using the licensed
antibodies.
▪ F-star Therapeutics Announces a License
Agreement with Takeda
▪ Under the agreement, F-star grants
Takeda a worldwide, exclusive royalty-
bearing license for bispecific antibody
against an immuno-oncology target using
F-star’s proprietary Fcab™ and mAb2 ™
platforms

43
Company Name Type
Amount /
Duration
Year Key Pointers
Grant $ 650,000
March,
2023
▪ Takeda Pharmaceutical announced more than $650,000 in grant
funding was awarded to 18 organizations through the Improving
Health Equity in Cancer: A Community Grant Program
▪ The grants were provided to patient advocacy organizations that
are helping to address the needs of medically underserved
people with cancer through community-based initiatives
Acquisition
of Licensing
Agreement
-
January
2023
▪ Takeda has entered into an exclusive licensing agreement with
HUTCHMED (China) Limited and its subsidiary HUTCHMED
Limited, for the further development and commercialization of
fruquintinib outside of mainland China, Hong Kong and Macau
Latest Deals - Mergers and Acquisitions

44
xx
xx xx
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
▪ According to Takeda Pharmaceutical
Company's 2022 financial report, the
company had revenue of $31.8 Bn in 2022
▪ The net profit margin of Takeda
Pharmaceutical has increased by 22%
from 2022
▪ Revenue generated by Takeda
Pharmaceutical Company in 2022 reflects
the company's continued growth and
success in the healthcare industry
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

45
4.2.2 Company 2
Founded in:
HQ:
Type:
Revenue:
Website:
Solutions offered by Company
Drugs Indications
Drugs for Cancer Recent Activity / Press Coverage
Illustrative

46
4.2.2 Company 2 (continued)
Major Distribution Partners Major Vendor Partners
Partnerships Ecosystem
Illustrative

47
Company Name Type
Amount /
Duration
Year Key Pointers
Latest Deals - Mergers and Acquisitions
Illustrative

48
xx xx xx
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
▪ Please be aware that this sample report is
report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
interest
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

5. Reimbursement Scenario

50
5.1 Reimbursement Regulation in Japan
The reimbursement scenario in the US cancer market is complex and can vary
depending on the specific treatment, setting of care, and insurance coverage.
Here are some key points to consider:
▪ Medicare:
o Medicare is a federal health insurance program for people aged 65 and
older, as well as people with certain disabilities or health conditions
o Medicare covers many cancer treatments, including chemotherapy,
radiation therapy, and some immunotherapies
o However, coverage can be subject to strict guidelines and restrictions,
such as the requirement for prior authorization
▪ Medicaid:
o Medicaid is a joint federal-state program that provides health insurance
for people with low incomes
o Medicaid coverage for cancer treatments can vary by state, and may be
subject to limits on the amount and type of treatment covered
▪ Private Insurance:
o Private insurance coverage for cancer treatments can also vary widely
depending on the insurer and the specific policy
o Some policies may have high out-of-pocket costs, such as deductibles
and co-pays, while others may have more comprehensive coverage
Medicare and Medicaid together provide
health insurance coverage for more than
4 in 10 Americans
Medicare
17%
Medicaid
and CHIP
21%
Employer-Sponsored
49%
Other Private
3%
Other Public
1%
Uninsured
9%
Health Insurance Coverage, 2022
Illustrative

51
5.1 Reimbursement Regulation (continued)
▪ Affordable Care Act:
o Affordable Care Act (ACA) includes provisions to help improve access to cancer treatments by requiring insurers to cover
certain preventive services, including cancer screenings, without co-pays or deductibles
o It also includes protections for people with pre-existing conditions, such as cancer
▪ Reimbursement for New Treatments:
o Reimbursement for new cancer treatments can be a complex and lengthy process, as insurers and government programs
often require evidence of safety and effectiveness before providing coverage
o This can create challenges for companies developing and marketing new treatments
▪ Value-Based Care:
o There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focusing on the
value of treatments rather than simply the volume of treatments
o Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
Illustrative

52
5.1 Reimbursement Regulation (continued)
Coverage Penetration (% Total Population) Source of Funding
Spend on Healthcare (%of Current Health Expenditure)
Reimbursement Market Trends
 Public healthcare coverage is provided by the government and includes programs like
Medicare and Medicaid
 Medicare is a federal program that provides healthcare coverage to individuals who
are 65 years of age or older, as well as certain younger people with disabilities
 Medicaid is a joint federal-state program that provides healthcare coverage to
individuals with low income and limited resources
▪ Shift towards value-based care has been a significant trend in the US healthcare system, with payers and providers increasingly focused on improving patient
outcomes and reducing costs
▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which
incentivize providers to deliver high-quality, cost-effective care 38.9%
37.1%
35.6%
32.5%
31.5%
44.0%
46.0%
47.7%
51.0%
51.8%
2017 2018 2019 2020 2021 2022 2023
Government Expenditure
Private Health Insurance
Out of Pocket
Other
NA NA
100% 100% 100% 100% 100%
xx xx xx xx xx
2012 2013 2014 2015 2016
Public Healthcare
Coverage
Private Coverage
6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy)
14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy)
Illustrative

53
5.2 Reimbursement Process for Diagnosis
The reimbursement process in the US healthcare system can be complex and can vary depending on the type of healthcare service,
the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process:
▪ Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient
▪ Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the
service provided
▪ Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for
reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential
errors or fraud
▪ Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service
provided, based on the negotiated payment rates or fee schedule
▪ Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost
of the service, such as deductibles, co-payments, or co-insurance
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
Illustrative

54
5.3 Reimbursement Process for Treatment
The reimbursement process in the US healthcare system can be complex
and can vary depending on the type of healthcare service, the healthcare
provider, and the insurance coverage. Here are the general steps involved
in the reimbursement process:
▪ Service or Treatment Provided: The healthcare provider performs a
service or treatment for the patient
▪ Billing: The healthcare provider submits a claim to the insurance
company or other payer, requesting reimbursement for the service
provided
▪ Adjudication: The insurance company or other payer reviews the claim
to determine whether it meets the criteria for reimbursement. This can
involve verifying the patient's eligibility, reviewing the treatment
provided, and checking for any potential errors or fraud
▪ Payment: If the claim is approved, the insurance company or other
payer reimburses the healthcare provider for the service provided,
based on the negotiated payment rates or fee schedule
FDA
Private Payers Public Payers
Health Technology Assessment
Payment
Coverage
Coding
Coding depends on availability code while coverage and
payment process decisions are made through an HTA.
Market Authorization
1 3
2
Illustrative

55
5.4 Reimbursement Process - Medicare
Medicare
Population Covered
▪ 100% population is covered under this scheme
▪ Citizen’s contribute to this scheme which then earns an interest. There is Basic Healthcare Sum (BHS) cap which limits the maximum contribution to an
individuals Medicare account
Provider Restrictions/
Selection
Services can be claimed from Medicare-approved institutions only (14 public hospitals, 10 private hospitals, 7 public community centers, 1 private community
center and over 100 surgery centers, dialysis centers, colonoscopy centers and screening centers)
Services Covered
▪ Medicines under SDL and MAF Plus can be bought from the money saved in this account
▪ Money can be also be claimed for antiretroviral drugs for HIV, Desferrioxamine drug for treatment of thalassemia and immuno-suppressant drugs for organ
transplant
▪ Money from this account can be used to pay Medishield premiums and Integrated Shield Plan premiums, subject to withdrawal limits
▪ Patients above 65 years of age can claim under Flexi-Medicare and further reduce their out-of-pocket expenses by using up to $200 per patient per year from
their Medicare account
▪ Excluded: Traditional drugs such as Herbal and Ayurveda cannot be claimed from Medicare account; Drugs used for cosmetic purposes such as slimming pills
and hair loss pills cannot be claimed from this account
Level of Coverage/ Assurance
▪ Approved chronic conditions and vaccinations, health screenings as outpatient treatments can be paid with Medicare up to $500 per account per year, however
a cash copayment of 15% is applicable
▪ Inpatient hospitalization, up to $450 per day + surgical limits according to Table of Surgical Procedures
▪ Approved day surgeries up to $300 per day + surgical limits according to Table of Surgical Procedures
▪ Outpatient scans/ diagnostics for cancer up to $600 per year per patient, and up to $300 for other medical conditions
▪ Chemotherapy (includes analgesic medication and suppressive treatments such as neuroendocrine and nuclear medicine treatments) up to $1,200 per month
per patient
▪ Renal dialysis up to $450 per patient per month
▪ Other treatments are also approved with various sub-limits for withdrawal
Mechanism of Coverage
▪ DRG with Activity Based Funding for public providers
▪ Block funding with DRG for providers not covered under ABF
Financial Feasibility ▪ The Basic Healthcare sum has been increased by more than 4.4% in 2017 on account of increasing costs of healthcare. This is an individual account
Illustrative

56
5.5 Reimbursement Process - Medicaid
Medicaid
Population Covered
▪ 38% population is covered under this scheme
▪ Medicare covers individuals who are aged 65 and older, as well as those with certain disabilities or end-stage renal disease
Provider Restrictions/
Selection
Services can be claimed from Medicaid-approved institutions only (14 public hospitals, 10 private hospitals, 7 public community centers, 1 private community
center and over 100 surgery centers, dialysis centers, colonoscopy centers and screening centers)
Services Covered
▪ Medicines under SDL and MAF Plus can be bought from the money saved in this account
▪ Money can be also be claimed for antiretroviral drugs for HIV, Desferrioxamine drug for treatment of thalassemia and immuno-suppressant drugs for organ
transplant
▪ Money from this account can be used to pay Medishield premiums and Integrated Shield Plan premiums, subject to withdrawal limits
▪ Patients above 65 years of age can claim under Flexi-Medicaid and further reduce their out-of-pocket expenses by using up to $200 per patient per year from
their Medicaid account
▪ Excluded: Traditional drugs such as Herbal and Ayurveda cannot be claimed from Medicaid account; Drugs used for cosmetic purposes such as slimming pills
and hair loss pills cannot be claimed from this account
Level of Coverage/ Assurance
▪ Approved chronic conditions and vaccinations, health screenings as outpatient treatments can be paid with Medicaid up to $500 per account per year, however
a cash copayment of 15% is applicable
▪ Inpatient hospitalization, up to $450 per day + surgical limits according to Table of Surgical Procedures
▪ Approved day surgeries up to $300 per day + surgical limits according to Table of Surgical Procedures
▪ Outpatient scans/ diagnostics for cancer up to $600 per year per patient, and up to $300 for other medical conditions
▪ Chemotherapy (includes analgesic medication and suppressive treatments such as neuroendocrine and nuclear medicine treatments) up to $1,200 per month
per patient
▪ Renal dialysis up to $450 per patient per month
▪ Other treatments are also approved with various sub-limits for withdrawal
Mechanism of Coverage
▪ DRG with Activity Based Funding for public providers
▪ Block funding with DRG for providers not covered under ABF
Financial Feasibility ▪ The Basic Healthcare sum has been increased by more than 4.4% in 2017 on account of increasing costs of healthcare. This is an individual account
Illustrative

6. Methodology & Scope

Research Methodology
▪ Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the
key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive
overview of the competitive landscape to help our clients make informed strategic decisions
▪ We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial
phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government
and regulatory published material, technical journals, trade magazines, and paid data sources
▪ For forecasting, the following parameters are considered:
❑ Market drivers and restraints along with their current and expected impacts
❑ Technological scenario and expected developments
❑ End use industry trends and dynamics
❑ Trends in the consumer behavior
❑ Regulatory scenario and expected developments
❑ Current capacity and expected capacity additions up to 2030
▪ We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected
market growth rate
▪ We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-
sensitive, reflecting the most recent value and volume of the market across regions
▪ All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs)
▪ Currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion (Mn/Bn)

Analysis Methodology
Our Analysis Methodology involves three critical stages:
Market Trends
Market Sizing &
Analysis
Data Triangulation &
Validation
Analysis &
Interpretation
Insights
Presentation &
Reporting
Market Data Analysis
& Statistical Model
Interpretation &
Presentation
Secondary
Research
Proprietary
Database
Data
Collection
Primary
Research

Data Triangulation & Data Validation
Bottom Up Approach
Summarization of revenue
generated from companies
to arrive at total market size
Revenue generated by products &
services offered by companies
Validation from
Primary Interview
Final
Market
Size
Top Down Approach
Final Market size break up to
rest of segmentation
Arriving at market size
of each segment
Validation from
Primary Interview
Final
Summary

Key Benefits for Stakeholders from this Report
Study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent
investment pockets
Our tools provides stakeholders with a cohesive understanding of the industry outlook, considering the qualitative and
quantitative industry variables
Comprehensive analysis of factors that drive and restrict the market growth is provided
Comprehensive quantitative analysis of the industry from 2022 to 2030F is provided to enable the stakeholders to capitalize on
the prevailing market opportunities
Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally
Our rigorous data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater
understanding of the industry space, supply chain, price fluctuations, competitive landscape, and other vital factors

2022
2023-
2030
Report Attribute
Quantitative Units
Report Coverage
Customized Report
Pricing and purchase
options
Revenue in USD Million/Billion (Mn/Bn)
Market Overview, Revenue Forecast, Market
Segmentation, Growth Factors and Trends,
Company Profiles, Competitive Landscape,
Regulatory Landscape, Future Opportunities
Report Customization (3 to 5 working days)
with purchase. We will provide you with data
that is currently not a part of our scope as a
part of customization
Avail customized purchase options to meet
your exact research needs
Details
Time Frame
Base Year for
Estimation
Forecast
Period

Insights10 is a healthcare focused market
research firm founded with an aim of being an
insights driven company in the data driven world
and delivering actionable insights that can drive
decision and strategy making process for
businesses
www.insights10.com
Lifesciences Market
Research Reports you
can trust

www.insights10.com
A large database of over 30,000 syndicated
market research reports in Healthcare Services
and healthcare sector at global, regional as well as
country level. We also provide customized
research reports tailor made to suit your needs
Get actionable insights to
take informed business
decisions

Our qualitative, acute, and result-oriented market
research reports provide a comprehensive
understanding of the business scenario and the
latest trends related to the life sciences market
Elevate your business plans
with in-depth market analysis
and industry intelligence
www.insights10.com

Whether you are looking to expand into new
areas, develop new products, or take advantage
of new opportunities we have reports to help you
accelerate and improve your plans by identifying
unique growth prospects.
Gain a competitive edge with
Insights10's customized
healthcare research solutions
www.insights10.com

Healthcare
Services
Clinical
Trials
OTC &
Nutraceuticals
Healthcare Services
(Diseases & Drugs)
Digital
Health
Medical
Devices
across various categories
Market Research Reports

FEATURED REPORTS FREE SAMPLE REPORTS
TRENDING TOPICS

1200+
Reports
Published
Annually
30000+
Life science
Market Research
Reports
22000+
Country
Specific
Reports
2000+
Rare & orphan
Disease
Reports
What makes us different?

Market Overview
Growth Drivers &
Growth Restraints
Market Segmentation
Market Share Factors Driving Future Growth
Reimbursement Scenario
Policy & Regulatory
Landscape
Key Company Profiles
Epidemiology &
Disease type
Competitive Landscape
insights on
which our
reports are
based
1
2
3
4
5
6
10
9
8
7
Table of Contents

Subscription
Regulatory
Compliance
Competitive
Intelligence
Conference
Coverage
Full-Time
Engagement
Database
Service
Primary
Research
Customized
Reports
Market Research
Reports
Our Services

Research Projects Done
Over the years, we have developed an in-depth experience of executing
market analysis at global, regional & country specific level in life sciences.
Our team has
conducted market
research across 62+
global markets in
America, Europe,
Middle East, Africa and
Asia Pacific regions

Our Research Process
01 03
02 04 05
Identification of
Data
Collection of
Data
Market
Dynamics
Collaboration
of Data
Verification &
Analysis

Statistical Databases
Data
Sources
We have access to multiple highly
reliable free and subscription data
sources. We have many years of
experience to understand which
sources are more dependable for what
and which to prefer for the reliable and
latest information.
Company Websites/Annual Reports
Trade Publications
Online Databases
Published Research Reports
Whitepapers
Press Releases of Key Market Players

What kind of data is presented
in our reports?
Our reports present data, which is:
The report is
prepared using a
proven methodology
and insightful
research
Reliable
The data is prepared
by a team of highly
qualified &
experienced research
analysts & vetted by
our local associates
Expert-verified
Allowing you to
confidently make
smarter business
and strategic
decisions
Real
Covers everything
you would need to
know about the
market including
market size,
competitive analysis
& much more
Comprehensive
You do not have to
be a market expert
to understand what
really is happening
on the market and
how it works
Easy to read

“The business decision-making process is no longer as
straightforward as it used to be. It requires insights
generated at the right time, based on reliable data
interpreted in a nuanced manner for each market.
We at Insights10 are building the future of market
research and are committed to providing our clients with
the right intelligence and insights to make business
decisions quickly and efficiently.
Insighs10 is a unique platform that combines deep
domain expertise, nuanced data at a country and
functional area level, and years of experience working
with some of the best organizations in the world,
generating insights that provides substantial competitive
advantage.”
Dr. Purav Gandhi
Founder & CEO

Purav is a physician and an entrepreneur
with 12+ years of experience in Healthcare
& Life Sciences industry spanning across
strategy, market access, health informatics
and RWE, digital health, analytics and data
science. Purav studied medicine from
Gujarat University and also completed his
MBA from IIM-Kozhikode. Purav started
his career with Deloitte working on strategy
consulting engagements and also co-
founded ConvergeHealth by Deloitte.
Anish has 15+ years of experience
in management consulting in the
Life Sciences sector, and has
worked with diverse multinational
firms in the US, India, Middle East
and APAC regions. His primary
area of interest is Customer and
Market Strategy, Market Access,
and Digital Health with special
focus on emerging markets like
Africa, Middle East and APAC.
Dr. Purav Gandhi
Founder & CEO
Anish Swaminathan
Director
Leadership Team
Mukesh is an engineering graduate with
an MBA in Marketing. He is a seasoned
healthcare market research & marketing
professional with a progressive
experience of over 20 years in Life
Sciences, Pharma and Medical Device
sectors. With an in-depth understanding
of primary research, he has conducted
hundreds of interviews of various
stakeholders in pharma & healthcare &
completed several research projects
across life sciences industry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across diff.
markets (America, Europe, Africa, APAC
and Middle East). Her areas of expertise
include: Indentifying emerging trends in life
sciences industry, Competitor landscape
assessment, Disease opportunity
assessments etc. She is a pro in secondary
and primary research with a deep domain
expertise in healthcare sector.
Mukesh Nayak
Head – Marketing & Research
Ritu Baliya
Engagement Manager

Web: www.insights10.com
Email: insights@insights10.com
Call: (+91) 931 639 7935
WhatsApp: (+91) 931 639 7935
We would be happy to help.
Do you have
any questions?

www.insights10.com
Thank you
We truly appreciate your business and
look forward to serving you.

Japan Patient Support Programs (PSP) Market Analysis Sample Report

Recommended

Recommended

More Related Content

Similar to Japan Patient Support Programs (PSP) Market Analysis Sample Report

Similar to Japan Patient Support Programs (PSP) Market Analysis Sample Report (20)

More from Insights10

More from Insights10 (20)

Recently uploaded

Recently uploaded (20)

Japan Patient Support Programs (PSP) Market Analysis Sample Report